When the granulated botanical powder is compressed into oral tablets intended for weaned piglets and growing poultry, the central processing risk shifts from chemical degradation to moisture-induced sticking and capping on high-speed rotary presses. The finished tablet is manufactured under 21 CFR 211 current good manufacturing practice where the product is registered as a veterinary pharmaceutical, and the core blend is tested against the general tablet monograph of the Veterinary Pharmacopoeia of the People's Republic of China (2020 edition) for hardness, friability, and disintegration. At direct compression loadings of 8.0–15.0% w/w active powder, the material is blended with microcrystalline cellulose, croscarmellose sodium, and colloidal silicon dioxide in a bin blender for 20 min, then lubricated with magnesium stearate at 0.5–1.0% w/w for no more than 3–5 min to prevent overlubrication and dissolution slowdown. At wet granulation loadings of 15.0–25.0% w/w, the powder is pre-mixed with filler in a high-shear mixer, granulated with 5% w/v povidone K30 solution, fluid-bed dried at 60–65 °C inlet temperature to a final moisture of ≤5.0%, and milled through an 0.8 mm screen before compression. Compression on a 16-station rotary tablet press operating at 8–18 kN compression force produces tablets with hardness 60–80 N, friability ≤1.0%, and disintegration ≤30 min in water at 37±2 °C. The terminal dosage form is an immediate-release oral tablet containing 0.5 g or 1.0 g of Qishen Jianwei Powder per unit. Tooling is maintained at 40–50% RH because the hygroscopic botanical powder can pick up surface moisture and cause picking when relative humidity exceeds 60%; dwell time is held below 30 ms to reduce elastic recovery and capping. Published data for this specific polyherbal mixture at loadings above 25% w/w is limited; formulators should verify tabletability by compact simulation before transferring to production-scale tooling.

The batch-to-batch variability of the incoming botanical powder affects tabletability more than the granulation method itself. If the saponin and polysaccharide fractions vary by more than ±10% of the certificate-of-analysis value, the wet massing endpoint shifts and the resulting granulate may require additional binder to maintain the same hardness profile. Granules with bulk density below 0.45 g/mL tend to fill die cavities unevenly on rotary presses, producing weight variation above ±5%; densification by roller compaction at 0.60–0.75 g/cm³ ribbon density is used to restore uniform filling. Aqueous film coating with hydroxypropyl methylcellulose at 2.0–3.0% w/w tablet weight is applied only if moisture protection is required; the coating pan inlet air is set to 50–60 °C, and the product temperature is kept below 40 °C to avoid thermal loss of heat-sensitive marker compounds.

What Process Parameters Govern Sterile Injectable Preparations from Botanical Powder?

Injectable formulations do not use the powder as a direct excipient. Instead, a clarified aqueous extract is prepared and sterile-filtered before filling as a parenteral grade solution. Manufacturing operations for aseptic filling fall under EU GMP Annex 1 and ISO 14644-1:2015 cleanroom classification; bacterial endotoxin control is verified by USP <85> or an equivalent pharmacopoeial method, and residual solvent testing follows VICH GL18 where a mixed ethanol-water extraction solvent is introduced. The extraction step starts with 10.0–20.0% w/v botanical powder in purified water, heated to 95–100 °C for 60–120 min, then chilled to 4–8 °C for 12–24 h to precipitate high-molecular-weight polysaccharides and pectin-like material. After centrifugation at 10,000–15,000 × g, the supernatant is filtered through 0.45 µm and then 0.22 µm polyethersulfone membranes. The filtrate is concentrated and standardized to 0.5–2.0% w/v total solids before aseptic filling into 10 mL or 50 mL Type II glass vials. The terminal dosage form is a sterile injectable solution for intramuscular or subcutaneous administration in cattle, swine, or equine species, only where the regulatory authorization explicitly includes injection.

The main process failure occurs at membrane filtration. Pectin-like polysaccharides and aggregated proteins form gel layers that can reduce normalized flux by 50–70% within 20–30 min when clarification is insufficient. Cross-flow filtration with a 100 kDa MWCO membrane operated at 0.5–1.5 bar transmembrane pressure may be evaluated, but pilot qualification is required because low-molecular-weight saponins may partially pass into the permeate or bind to the membrane depending on pH and ionic strength. Terminal steam sterilization at 121 °C for 15 min is only feasible if the extract pH is maintained between 5.5 and 6.5; alkaline pH accelerates saponin hydrolysis and produces haze. If terminal sterilization is not chemically feasible, aseptic filtration and filling in an ISO 14644-1:2015 Grade A environment with Grade B background is the conservative control strategy. The process must also include a pre-filtration bioburden reduction step, because a high microbial load in the extraction vessel can raise endotoxin levels beyond the acceptable limit of 0.5 EU/mg for parenteral products and compromise filter integrity.

Capsule Fill Mechanics and Excipient Selection

Direct encapsulation of the raw botanical powder is constrained by its low bulk density and variable flow character. For hard gelatin or hydroxypropyl methylcellulose capsules, the active powder is typically loaded at 30.0–60.0% w/w with lactose monohydrate, croscarmellose sodium, and colloidal silicon dioxide. The blend is tested for flow by USP <1174> powder flow methods, and dissolution is evaluated by USP <711> apparatus II at 50 rpm in 0.1 N HCl or buffer as specified in the product submission. Roller compaction is used when the raw powder bulk density falls below 0.45 g/mL; the compacted ribbon is milled to a granulate with bulk density 0.60–0.75 g/cm³ before encapsulation on an intermittent dosator machine operating at 40–60 capsules/min. The terminal dosage form is a hard capsule containing 0.25 g or 0.50 g of active powder per unit, intended for companion animals or equine patients where discrete unit dosing is required.

Moisture control is the main stability risk. Capsule shells exposed to relative humidity above 60% can absorb water, become brittle, or undergo gelatin cross-linking; finished capsules are therefore transferred immediately into HDPE bottles with desiccant canisters and induction-sealed closures. Colloidal silicon dioxide at 1.0–2.0% w/w improves blend flow but can retard wetting and slow dissolution if mixed longer than 10 min under high shear. Magnesium stearate is limited to 0.5% w/w and is added last to avoid hydrophobic film formation on granulate surfaces. Capsule filling weight variation should be controlled to ±5% for unit doses above 250 mg, and the process is typically run at 40–50% RH in the encapsulation suite to preserve shell dimensional stability.

For medicated premix lines producing finished feed for broiler and swine operations, the botanical powder is incorporated as a micro-ingredient in a carrier-based premix rather than as direct feed addition. The premix is manufactured under ISO 22000:2018 food safety management and, where the formula is listed as a feed additive, within the scope of Regulation (EC) No 1831/2003. Active loading in the intermediate premix is typically 0.5–2.0% w/w of the botanical powder; final complete feed inclusion is 500–2000 g/t, equivalent to 0.05–0.20% w/w. Processing uses a ribbon mixer with a coefficient of variation target of ≤5% after 15 min mixing, following sequential geometric dilution of the active powder into a free-flowing carrier with particle size between 250 µm and 500 µm. The terminal product is a 25 kg multi-wall paper bag of medicated premix for farm or feed-mill dilution into complete compound feed. The major processing limitation is segregation during handling: if the botanical powder particle size is more than 30 µm below the carrier median, vibration during transport can strip the active fraction from the carrier and produce sampling variability above 10%.

Granulation Endpoints for Water-Soluble Drinking-Water Products

The transition from dry powder to a water-soluble granule involves a moisture-activation step that must be controlled by product temperature rather than inlet temperature alone. The active powder is incorporated at 10.0–25.0% w/w into a high-shear granulator with maltodextrin or sucrose as carrier, povidone K30 at 3.0–5.0% w/w as binder, and purified water as granulation fluid. Wet massing time is kept between 3 min and 6 min; overdosing water or extended massing creates dense agglomerates that resist later dissolution. Fluid-bed drying is set to 55–65 °C inlet air, but the product temperature is maintained at ≤40 °C because polysaccharide fractions can undergo Maillard reactions with reducing sugar carriers above that threshold, causing darkening and loss of thin-layer chromatography marker intensity. Final granule moisture is controlled to ≤3.0%, and the particle size is fractionated to 200–850 µm. Dissolution in water at 25 °C should be complete within 5 min with gentle stirring; the terminal product is a water-soluble granule packed in 100 g or 500 g laminated foil pouches for drinking-water administration to poultry or swine.

The critical formulation boundary is the acid sensitivity of the clarified water fraction. Effervescent or acidified systems with pH below 4.0 can precipitate saponin components and produce turbidity or sediment in the drinking-water line. Citrate or phosphate buffers are used to hold the reconstituted solution at pH 5.0–6.0. The inclusion of anticaking agents is not recommended in water-soluble granules because hydrophobic flow aids can float on the water surface and delay wetting. When the product is administered through a proportioning medicator, the stock solution should be filtered through a 100 µm in-line strainer to prevent nozzle clogging by undissolved botanical fragments. Published data for this specific granule configuration is limited, so the granulation endpoint must be established by pilot-scale trials using the actual batch of Qishen Jianwei Powder rather than a model herbal extract.

Direct oral powders for feed top-dressing in weaned piglets present a different blend-to-dose uniformity challenge than wet granulated systems because there is no granulation step to lock the active particle into a larger agglomerate. The direct powder is commonly formulated as 70.0–90.0% w/w active botanical powder with lactose monohydrate q.s. to 100%, and the dose is dispensed as 1.0–2.0 g per animal per day according to the marketing authorization. Manufacturing uses a V-blender or double-cone blender filled to 60–70% of rated capacity and mixed for 15–20 min at 15–20 rpm. The blend is sifted through a 420 µm mesh to break soft agglomerates, then filled by auger filler into 500 g polyethylene jars with induction-sealed closures. The terminal dosage form is an oral top-dress powder for group or individual administration in swine and poultry. The main process boundary is blend segregation in the filler hopper; fill weight variation should be controlled to ±5%, and hopper levels should be maintained above 30% to avoid pressure-related segregation. If ambient humidity exceeds 60% RH, the powder should not be left exposed for more than 30 min because surface moisture reduces flow and causes bridging over the auger screw.

If a Liquid Oral Solution or Drench Is Required

Aqueous extraction is the first unit operation for a liquid oral solution or drench. The manufacturing process starts with 5.0–10.0% w/v botanical powder in purified water, heated to 90–95 °C for 45–60 min, then cooled rapidly to 4–8 °C to precipitate cold-insoluble polysaccharides. After centrifugation at 8,000–12,000 × g, the liquid is passed through a 0.45 µm filter and diluted to 0.5–1.0% w/v total solids. The pH is adjusted to 5.0–6.0 with citric acid or sodium citrate; potassium sorbate 0.1% w/v and sodium benzoate 0.1% w/v are added as preservatives. The terminal product is a liquid oral solution or drench in 100 mL or 500 mL HDPE dosing bottles for calves, piglets, or poultry. The nonsterile oral liquid must meet the microbial quality acceptance criteria of Ph. Eur. 5.1.4, and preservative efficacy is verified by Ph. Eur. 5.1.3 criteria A.

The main processing restriction is haze formation and sedimentation. Cold precipitation removes the bulk of pectin-like material, but residual pectin can complex with trace calcium ions in hard water and form a visible haze; the extraction water should therefore be softened or chelated with disodium EDTA at 0.01–0.05% w/v. High-temperature pasteurization at 85–90 °C for 15 min is preferred over autoclaving because prolonged exposure to 121 °C can reduce marker compound recovery and deepen color. If the solution is to be used through a drinking-water proportioner, the final dilution should be verified for clarity and filterability through a 100 µm screen; undissolved botanical residues above this size can block medicator diaphragms. Published data for the stability of this specific product in a liquid oral vehicle is limited, so real-time stability storage at 25 °C/60% RH and 40 °C/75% RH should be generated for the packaging configuration before commercial distribution.